Branched Stent Grafts

Branched Stent Grafts Market Outlook

The global branched stent grafts market is projected to reach approximately USD 2.84 billion by 2035, with a compound annual growth rate (CAGR) of around 6.5% from 2025 to 2035. This growth can be attributed to the rising prevalence of vascular diseases, increased geriatric population, and advancements in technology that enhance the effectiveness of stent graft procedures. Moreover, the growing awareness regarding the benefits of endovascular treatments over traditional surgical techniques is further driving the market. With the integration of innovative materials and designs, branched stent grafts are becoming a preferred option for treating complex vascular conditions. Additionally, favorable reimbursement policies and increased healthcare expenditure in emerging economies are expected to bolster market growth during the forecast period.

Growth Factor of the Market

The growth of the branched stent grafts market is significantly propelled by the increasing incidence of aortic aneurysms and peripheral artery diseases globally. These vascular conditions require specialized interventions, which have led to an escalated demand for advanced stenting solutions. Furthermore, technological advancements, such as the development of bioresorbable stents and drug-eluting stents, have contributed to improved patient outcomes and reduced complications, thereby instilling greater confidence among healthcare providers and patients alike in the use of branched stent grafts. The shift towards minimally invasive procedures is another crucial factor, as these approaches typically entail shorter recovery times and lower risks of postoperative complications. Additionally, the expansion of the healthcare infrastructure, particularly in developing nations, is facilitating greater access to advanced medical devices, thus enhancing market penetration. Lastly, the rise in clinical studies and trials evaluating the efficacy of branched stent grafts is expected to further validate their use and foster market growth.

Key Highlights of the Market

• The branched stent grafts market is anticipated to grow significantly with a CAGR of 6.5% from 2025 to 2035.
• North America holds a substantial share of the market due to favorable reimbursement policies and advanced healthcare infrastructure.
• Technological advancements are leading to increased adoption of branched stent grafts in clinical settings.
• The rising prevalence of aortic aneurysms and peripheral artery diseases is a significant growth driver.
• Minimally invasive surgeries are becoming more popular, contributing to the demand for branched stent grafts.

By Product Type

Thoracoabdominal Aortic Aneurysm Stent Grafts:

Thoracoabdominal aortic aneurysm stent grafts are specifically designed for the treatment of aneurysms occurring in the thoracic and abdominal sections of the aorta. These stent grafts are engineered to address the complexities associated with aneurysms that extend across both anatomical regions. Their design often includes branched components that facilitate blood flow to critical arteries, thus ensuring organ perfusion while effectively sealing off the aneurysm. The increasing number of thoracoabdominal aortic aneurysm cases, alongside advancements in stent technology, has contributed to the growing adoption of these specialized stent grafts. Moreover, comprehensive training programs for surgeons on the deployment of such devices have also fostered their usage in clinical practices.

Abdominal Aortic Aneurysm Stent Grafts:

Abdominal aortic aneurysm stent grafts are tailored for treating aneurysms located in the abdominal aorta, a condition that is particularly prevalent among older populations. These stent grafts are designed to provide a minimally invasive solution, allowing for quicker recovery times and reduced hospital stays compared to traditional open surgery. Their effectiveness in minimizing complications associated with abdominal aortic aneurysms has significantly bolstered demand in the market. The increasing awareness among healthcare professionals and patients about the benefits of early intervention using these stent grafts, alongside improved imaging technologies, has further propelled the growth of this segment.

Thoracic Aortic Aneurysm Stent Grafts:

Thoracic aortic aneurysm stent grafts are utilized for the treatment of aneurysms occurring in the thoracic aorta. The market for this segment is expanding due to the rising incidence of thoracic aortic aneurysms, which is often linked to lifestyle factors and comorbidities such as hypertension and atherosclerosis. These stent grafts provide a less invasive option for patients, thereby reducing the risk of complications and improving recovery times. Advancements in materials and graft designs, which enhance flexibility and conformability, have also contributed to the increasing adoption of thoracic aortic aneurysm stent grafts. Continuous research and development in this area are expected to lead to further innovations, thus driving market growth.

Peripheral Artery Disease Stent Grafts:

Peripheral artery disease (PAD) stent grafts are designed for individuals suffering from narrowing or blockages in peripheral arteries, commonly affecting the legs. This segment is witnessing notable growth owing to the increasing prevalence of PAD, particularly among the aging population and individuals with risk factors such as diabetes and obesity. The deployment of these stent grafts is primarily intended to restore blood flow and alleviate symptoms like pain and cramping, which can significantly impair quality of life. Technological enhancements that improve the efficacy and durability of PAD stent grafts are further fueling demand, making them a critical component of vascular intervention strategies.

Vascular Stent Grafts:

Vascular stent grafts encompass a broader range of devices used for various vascular conditions beyond aneurysms. These stent grafts play a crucial role in treating conditions such as stenosis and vascular malformations. The versatility of vascular stent grafts is a significant growth factor as they can be used in numerous anatomical locations, providing solutions for diverse patient needs. As medical technology advances, the designs of these stent grafts are becoming more sophisticated, incorporating features that enhance their performance and reduce the risk of complications. The increasing adoption of vascular stent grafts in interventional procedures, coupled with rising awareness of their benefits, continues to drive this segment of the market.

By Application

Endovascular Aneurysm Repair:

Endovascular aneurysm repair (EVAR) is a minimally invasive procedure that has gained significant traction for treating abdominal and thoracic aortic aneurysms. This method is preferred due to its reduced recovery time compared to traditional surgical approaches. The growing acceptance of EVAR among both medical professionals and patients is driving the demand for branched stent grafts, as they are integral to the success of this procedure. Furthermore, advancements in imaging technologies and stent designs have improved the outcomes of EVAR, thus bolstering its application in clinical settings. With an increasing number of patients opting for less invasive treatments, the EVAR segment is expected to continue its upward trajectory in the branched stent grafts market.

Peripheral Artery Disease Treatment:

The treatment of peripheral artery disease (PAD) using stent grafts represents a significant application within the market. The rising incidence of PAD, along with the associated complications such as limb ischemia and ulcers, has heightened the demand for effective treatment options. Stent grafts offer a solution that improves blood flow in affected arteries, alleviating symptoms and enhancing the quality of life for patients. The continual development of innovative stent designs tailored for PAD treatment is expected to drive growth in this application area. Additionally, as healthcare providers increasingly recognize the advantages of minimally invasive procedures for PAD management, the adoption of stent grafts in this context is likely to expand.

Others:

This category includes various applications that leverage branched stent grafts for other vascular conditions outside of aneurysms and peripheral artery disease. The versatility of these stent grafts allows their use in treating a range of vascular issues, including arteriovenous fistulas and vascular malformations. As healthcare technologies evolve, the application of branched stent grafts in diverse medical scenarios is becoming more prevalent. Continuous research is likely to uncover additional uses for these grafts, further enhancing their market presence. The growth of this segment is supported by increasing awareness and acceptance of endovascular solutions for managing complex vascular conditions.

By Distribution Channel

Hospitals:

Hospitals are the primary distribution channel for branched stent grafts, given their role as critical healthcare facilities providing comprehensive vascular care. The presence of specialized vascular surgeons and advanced medical technologies within hospitals facilitates the efficient deployment of stent grafts. As healthcare systems continue to evolve, hospitals are increasingly adopting minimally invasive procedures, thus boosting the demand for branched stent grafts. Additionally, collaborations between hospitals and stent manufacturers are enhancing the availability and accessibility of advanced stent graft options, further driving market growth in this distribution channel.

Ambulatory Surgical Centers:

Ambulatory surgical centers (ASCs) are gaining prominence as an important distribution channel for branched stent grafts, owing to their focus on outpatient surgical procedures. The trend towards performing vascular interventions in ASCs is driven by the benefits of reduced costs and shorter recovery times for patients. This shift in surgical practice is encouraging stent graft manufacturers to enhance their partnerships with ASCs, facilitating the adoption of these devices in outpatient settings. The increasing caseload of endovascular procedures being performed in ASCs is expected to significantly contribute to the growth of this segment in the branched stent grafts market.

Specialty Clinics:

Specialty clinics are dedicated healthcare facilities that focus on specific medical conditions, including vascular diseases. As experts in their respective fields, these clinics are well-equipped to provide targeted treatments, including the use of branched stent grafts for complex vascular interventions. The growing number of specialty clinics and their collaboration with stent manufacturers is increasing the availability and adoption of these advanced devices. Additionally, the rise in patient preference for specialized care and the trend toward personalized medicine are expected to further bolster the demand for branched stent grafts through this distribution channel.

Others:

The 'Others' category encompasses various distribution channels not classified under hospitals, ASCs, or specialty clinics. This may include online medical supply platforms, direct sales from manufacturers, or partnerships with outpatient care facilities. The expansion of e-commerce and telemedicine is gradually influencing how medical devices, including branched stent grafts, are marketed and distributed. As healthcare delivery models continue to transform, alternative distribution channels are expected to emerge, which could enhance the availability and accessibility of branched stent grafts to a broader array of healthcare providers and patients.

By Material Type

Nickel-Titanium Alloy:

Nickel-titanium alloy, often referred to as Nitinol, is a significant material used in the manufacturing of branched stent grafts due to its unique properties, including flexibility, strength, and biocompatibility. The use of Nitinol allows for the development of stent grafts that can adapt to the complex anatomy of the vascular system while providing effective support and sealing of aneurysms. The growing preference for Nitinol-based stent grafts is driven by their ability to minimize complications and improve patient outcomes, thus propelling market growth. As research continues to enhance the properties and performance of nickel-titanium alloys, this material is likely to maintain a strong presence in the branched stent grafts market.

Polytetrafluoroethylene:

Polytetrafluoroethylene (PTFE) is a widely used material in the production of branched stent grafts, primarily due to its excellent hydrophobic properties and biocompatibility. PTFE-coated stent grafts are designed to resist thrombosis and promote smooth blood flow, thereby reducing the risk of complications associated with vascular interventions. The demand for PTFE-based stent grafts is growing as healthcare providers seek effective solutions for managing complex vascular conditions. Innovations in PTFE manufacturing and coating technologies are further expected to enhance the performance and durability of stent grafts, driving the market forward.

Polyethylene Terephthalate:

Polyethylene terephthalate (PET) is another critical material utilized in branched stent grafts, recognized for its strength and resistance to stretching and tearing. PET grafts are often preferred for their ability to maintain structural integrity under various physiological conditions. The increasing focus on the development of durable and reliable stent grafts is fueling the demand for PET as a material of choice. Furthermore, ongoing innovations in PET processing techniques are likely to improve the overall performance of these grafts, contributing to market growth.

Dacron:

Dacron, a polyester material, is frequently employed in the fabrication of branched stent grafts due to its excellent mechanical properties and biocompatibility. Dacron grafts are known for their durability and resistance to infection, making them suitable for long-term vascular applications. The ongoing research into enhancing the properties of Dacron, such as incorporating surface coatings to reduce friction, is expected to further bolster the market. As medical professionals increasingly recognize the benefits of Dacron-based stent grafts, the demand for this material is anticipated to rise correspondingly.

Others:

The 'Others' category includes various alternative materials that may be utilized in the production of branched stent grafts, such as polyurethanes or composite materials. These innovative materials aim to enhance the performance, durability, and biocompatibility of stent grafts, addressing specific clinical needs. As research and development in biomaterials progress, these materials are likely to gain traction in the branched stent grafts market. The exploration of new materials offers opportunities for customization and optimization of stent graft designs, ultimately contributing to improved patient outcomes and market growth.

By Region

North America is currently the largest market for branched stent grafts, accounting for a significant share due to the advanced healthcare infrastructure, high prevalence of vascular diseases, and well-established regulatory frameworks. The region’s robust medical device market, along with favorable reimbursement policies, supports the adoption of innovative stent graft technologies. The CAGR for North America is estimated to be around 6.8%, reflecting strong growth potential driven by technological advancements and increased healthcare spending. Moreover, the presence of leading market players and a highly skilled surgical workforce further contribute to the dominance of this region in the branched stent grafts market.

Europe holds the second largest share in the branched stent grafts market, driven by increasing awareness of vascular diseases and the growing adoption of minimally invasive surgical techniques. The region benefits from a well-established medical device regulatory environment and significant investments in healthcare innovation. The rising geriatric population, coupled with an increase in lifestyle-related disorders, is expected to further enhance the demand for branched stent grafts. Countries such as Germany, France, and the United Kingdom are at the forefront of this growth, with their advanced healthcare systems and ongoing research initiatives in vascular intervention technologies.

Opportunities

The branched stent grafts market presents numerous opportunities for growth, particularly in emerging economies where healthcare infrastructure is rapidly evolving. Countries in Asia Pacific and Latin America are experiencing an increase in healthcare investments, which is fostering the adoption of advanced medical technologies, including branched stent grafts. As awareness of vascular diseases rises and access to healthcare improves, there is a significant opportunity for manufacturers to penetrate these markets with tailored solutions that meet the unique needs of local populations. Additionally, partnerships with local healthcare providers and governments could facilitate the introduction of innovative stent graft technologies, further driving market expansion. The integration of telemedicine and digital health solutions is another area ripe for development, enabling healthcare professionals to monitor patients remotely and enhance treatment outcomes.

Another promising opportunity lies in the ongoing research and development of next-generation stent grafts that incorporate novel materials and technologies. Innovations such as drug-eluting stents, bioresorbable materials, and advanced imaging techniques are set to transform the landscape of vascular interventions. As clinical trials continue to validate the effectiveness of these cutting-edge stent grafts, healthcare providers will be more inclined to adopt them, thus driving market growth. Additionally, the increasing focus on personalized medicine and patient-centric approaches in healthcare will pave the way for customized stent graft solutions tailored to the specific anatomical and pathological characteristics of individual patients, further enhancing treatment efficacy and patient satisfaction.

Threats

Despite the positive outlook for the branched stent grafts market, several threats could pose challenges to its growth trajectory. One significant concern is the stringent regulatory environment governing medical devices, which can delay product approvals and hinder market entry for new innovations. Manufacturers must navigate complex regulatory frameworks, which may vary across regions, thereby increasing operational costs and time to market. Additionally, the competitive landscape is becoming increasingly saturated as more companies enter the market, leading to price pressure and reduced profit margins. This scenario could compel manufacturers to compromise on product quality in order to remain competitive, potentially impacting patient safety and outcomes.

Furthermore, the rising cost of healthcare and the increasing scrutiny on medical device pricing could pose challenges for market players. As healthcare systems strive to cut costs while maintaining quality care, there may be increased pressure on manufacturers to provide cost-effective solutions. This can lead to reduced investments in research and development, stifling innovation and the introduction of new products into the market. Additionally, the growing trend of patient preference for alternative therapies, such as pharmacological treatments or lifestyle modifications, may further challenge the demand for surgical interventions using branched stent grafts.

Competitor Outlook

• Medtronic plc
• Boston Scientific Corporation
• Abbott Laboratories
• Terumo Corporation
• Cook Medical
• Cardinal Health, Inc.
• Johnson & Johnson
• Gore Medical
• Endologix, Inc.
• Vascular Solutions, Inc.
• Merit Medical Systems, Inc.
• Philips Healthcare
• Siemens Healthineers
• Rowe Scientific
• Asahi Intecc Co., Ltd.

The competitive landscape of the branched stent grafts market is characterized by the presence of several prominent players, each vying for market share through innovation, strategic collaborations, and aggressive marketing strategies. Leading companies such as Medtronic plc and Boston Scientific Corporation are at the forefront of technological advancements, continuously developing new stent graft solutions to address the evolving needs of the healthcare sector. These companies invest significantly in research and development, focusing on enhancing the performance and safety profiles of their products. Additionally, collaborations with leading hospitals and research institutions facilitate the exchange of knowledge and expertise, further driving innovation in this competitive landscape.

Furthermore, the market is witnessing an increase in mergers and acquisitions as companies seek to expand their product portfolios and market reach. For instance, Abbott Laboratories has made strategic acquisitions to bolster its presence in the vascular device market, enhancing its offerings with advanced stent graft technologies. Similarly, Cook Medical has expanded its product line through partnerships and collaborations, ensuring it remains competitive in the rapidly evolving healthcare landscape. Companies are also focusing on strengthening their distribution networks to enhance accessibility and availability of branched stent grafts in various regions, thereby increasing market penetration.

Emerging players in the branched stent grafts market are also gaining traction by introducing innovative solutions that cater to niche segments of the market. These companies are leveraging advancements in materials science and engineering to develop next-generation stent grafts that improve patient outcomes and reduce complications. For example, the incorporation of drug-eluting technologies and bioresorbable materials is gaining interest among healthcare providers. As these innovations continue to reshape the market, established players will need to adapt and stay ahead of emerging trends to maintain their competitive edge. Overall, the competitive landscape of the branched stent grafts market is dynamic, with a focus on innovation, collaboration, and strategic growth initiatives.

• 1 Appendix

  • 1.1 List of Tables
  • 1.2 List of Figures

• 2 Introduction

  • 2.1 Market Definition
  • 2.2 Scope of the Report
  • 2.3 Study Assumptions
  • 2.4 Base Currency & Forecast Periods

• 3 Market Dynamics

  • 3.1 Market Growth Factors
  • 3.2 Economic & Global Events
  • 3.3 Innovation Trends
  • 3.4 Supply Chain Analysis

• 4 Consumer Behavior

  • 4.1 Market Trends
  • 4.2 Pricing Analysis
  • 4.3 Buyer Insights

• 5 Key Player Profiles

  • 5.1 Cook Medical
    • 5.1.1 Business Overview
    • 5.1.2 Products & Services
    • 5.1.3 Financials
    • 5.1.4 Recent Developments
    • 5.1.5 SWOT Analysis
  • 5.2 Gore Medical
    • 5.2.1 Business Overview
    • 5.2.2 Products & Services
    • 5.2.3 Financials
    • 5.2.4 Recent Developments
    • 5.2.5 SWOT Analysis
  • 5.3 Medtronic plc
    • 5.3.1 Business Overview
    • 5.3.2 Products & Services
    • 5.3.3 Financials
    • 5.3.4 Recent Developments
    • 5.3.5 SWOT Analysis
  • 5.4 Endologix, Inc.
    • 5.4.1 Business Overview
    • 5.4.2 Products & Services
    • 5.4.3 Financials
    • 5.4.4 Recent Developments
    • 5.4.5 SWOT Analysis
  • 5.5 Rowe Scientific
    • 5.5.1 Business Overview
    • 5.5.2 Products & Services
    • 5.5.3 Financials
    • 5.5.4 Recent Developments
    • 5.5.5 SWOT Analysis
  • 5.6 Johnson & Johnson
    • 5.6.1 Business Overview
    • 5.6.2 Products & Services
    • 5.6.3 Financials
    • 5.6.4 Recent Developments
    • 5.6.5 SWOT Analysis
  • 5.7 Philips Healthcare
    • 5.7.1 Business Overview
    • 5.7.2 Products & Services
    • 5.7.3 Financials
    • 5.7.4 Recent Developments
    • 5.7.5 SWOT Analysis
  • 5.8 Terumo Corporation
    • 5.8.1 Business Overview
    • 5.8.2 Products & Services
    • 5.8.3 Financials
    • 5.8.4 Recent Developments
    • 5.8.5 SWOT Analysis
  • 5.9 Abbott Laboratories
    • 5.9.1 Business Overview
    • 5.9.2 Products & Services
    • 5.9.3 Financials
    • 5.9.4 Recent Developments
    • 5.9.5 SWOT Analysis
  • 5.10 Siemens Healthineers
    • 5.10.1 Business Overview
    • 5.10.2 Products & Services
    • 5.10.3 Financials
    • 5.10.4 Recent Developments
    • 5.10.5 SWOT Analysis
  • 5.11 Cardinal Health, Inc.
    • 5.11.1 Business Overview
    • 5.11.2 Products & Services
    • 5.11.3 Financials
    • 5.11.4 Recent Developments
    • 5.11.5 SWOT Analysis
  • 5.12 Asahi Intecc Co., Ltd.
    • 5.12.1 Business Overview
    • 5.12.2 Products & Services
    • 5.12.3 Financials
    • 5.12.4 Recent Developments
    • 5.12.5 SWOT Analysis
  • 5.13 Vascular Solutions, Inc.
    • 5.13.1 Business Overview
    • 5.13.2 Products & Services
    • 5.13.3 Financials
    • 5.13.4 Recent Developments
    • 5.13.5 SWOT Analysis
  • 5.14 Merit Medical Systems, Inc.
    • 5.14.1 Business Overview
    • 5.14.2 Products & Services
    • 5.14.3 Financials
    • 5.14.4 Recent Developments
    • 5.14.5 SWOT Analysis
  • 5.15 Boston Scientific Corporation
    • 5.15.1 Business Overview
    • 5.15.2 Products & Services
    • 5.15.3 Financials
    • 5.15.4 Recent Developments
    • 5.15.5 SWOT Analysis

• 6 Market Segmentation

  • 6.1 Branched Stent Grafts Market, By Application
    • 6.1.1 Endovascular Aneurysm Repair
    • 6.1.2 Peripheral Artery Disease Treatment
    • 6.1.3 Others
  • 6.2 Branched Stent Grafts Market, By Product Type
    • 6.2.1 Thoracoabdominal Aortic Aneurysm Stent Grafts
    • 6.2.2 Abdominal Aortic Aneurysm Stent Grafts
    • 6.2.3 Thoracic Aortic Aneurysm Stent Grafts
    • 6.2.4 Peripheral Artery Disease Stent Grafts
    • 6.2.5 Vascular Stent Grafts
  • 6.3 Branched Stent Grafts Market, By Material Type
    • 6.3.1 Nickel-Titanium Alloy
    • 6.3.2 Polytetrafluoroethylene
    • 6.3.3 Polyethylene Terephthalate
    • 6.3.4 Dacron
    • 6.3.5 Others
  • 6.4 Branched Stent Grafts Market, By Distribution Channel
    • 6.4.1 Hospitals
    • 6.4.2 Ambulatory Surgical Centers
    • 6.4.3 Specialty Clinics
    • 6.4.4 Others

• 7 Competitive Analysis

  • 7.1 Key Player Comparison
  • 7.2 Market Share Analysis
  • 7.3 Investment Trends
  • 7.4 SWOT Analysis

• 8 Research Methodology

  • 8.1 Analysis Design
  • 8.2 Research Phases
  • 8.3 Study Timeline

• 9 Future Market Outlook

  • 9.1 Growth Forecast
  • 9.2 Market Evolution

• 10 Geographical Overview

  • 10.1 Europe - Market Analysis
    • 10.1.1 By Country
      • 10.1.1.1 UK
      • 10.1.1.2 France
      • 10.1.1.3 Germany
      • 10.1.1.4 Spain
      • 10.1.1.5 Italy
  • 10.2 Asia Pacific - Market Analysis
    • 10.2.1 By Country
      • 10.2.1.1 India
      • 10.2.1.2 China
      • 10.2.1.3 Japan
      • 10.2.1.4 South Korea
  • 10.3 Latin America - Market Analysis
    • 10.3.1 By Country
      • 10.3.1.1 Brazil
      • 10.3.1.2 Argentina
      • 10.3.1.3 Mexico
  • 10.4 North America - Market Analysis
    • 10.4.1 By Country
      • 10.4.1.1 USA
      • 10.4.1.2 Canada
  • 10.5 Branched Stent Grafts Market by Region
  • 10.6 Middle East & Africa - Market Analysis
    • 10.6.1 By Country
      • 10.6.1.1 Middle East
      • 10.6.1.2 Africa

• 11 Global Economic Factors

  • 11.1 Inflation Impact
  • 11.2 Trade Policies

• 12 Technology & Innovation

  • 12.1 Emerging Technologies
  • 12.2 AI & Digital Trends
  • 12.3 Patent Research

• 13 Investment & Market Growth

  • 13.1 Funding Trends
  • 13.2 Future Market Projections

• 14 Market Overview & Key Insights

  • 14.1 Executive Summary
  • 14.2 Key Trends
  • 14.3 Market Challenges
  • 14.4 Regulatory Landscape

Segments Analyzed in the Report

The global Branched Stent Grafts market is categorized based on

By Product Type

• Thoracoabdominal Aortic Aneurysm Stent Grafts
• Abdominal Aortic Aneurysm Stent Grafts
• Thoracic Aortic Aneurysm Stent Grafts
• Peripheral Artery Disease Stent Grafts
• Vascular Stent Grafts

By Application

• Endovascular Aneurysm Repair
• Peripheral Artery Disease Treatment
• Others

By Distribution Channel

• Hospitals
• Ambulatory Surgical Centers
• Specialty Clinics
• Others

By Material Type

• Nickel-Titanium Alloy
• Polytetrafluoroethylene
• Polyethylene Terephthalate
• Dacron
• Others

By Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

Key Players

• Medtronic plc
• Boston Scientific Corporation
• Abbott Laboratories
• Terumo Corporation
• Cook Medical
• Cardinal Health, Inc.
• Johnson & Johnson
• Gore Medical
• Endologix, Inc.
• Vascular Solutions, Inc.
• Merit Medical Systems, Inc.
• Philips Healthcare
• Siemens Healthineers
• Rowe Scientific
• Asahi Intecc Co., Ltd.